Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), announced today the advancement to large-scale production of BMC128, its Live Bacterial Product (LBP) candidate consortium. […]
Federation Bio, a microbial therapeutics company targeting diseases in which the human microbiome can play a curative role, today announced that it has closed a $50 million Series A financing and expanded its leadership team. […]
Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, today announced it has been awarded funding of $7.4 million, with the potential […]
Locus Biosciences announced today that it has signed a contract with the Biomedical Advanced Research and Development Authority (BARDA) to co-fund development of LBP-EC01, a CRISPR Cas3-enhanced bacteriophage (crPhage™) product that will target Escherichia coli […]
Arranta Bio (“Arranta”), a leading microbiome contract development and manufacturing organization (CDMO), today announced the mechanical completion of GMP suites at its Watertown, MA commercial-ready facility. Arranta is investing more than $100M in 2020 to […]
Chr. Hansen Holding A/S (“Chr. Hansen”) has entered into an agreement to acquire all of the shares of Jennewein Biotechnologie GmbH (“Jennewein”), which is a leading player in the Human Milk Oligosaccharides (“HMO”) market The […]
Siolta Therapeutics, a clinical-stage biotech company, announced today it has raised $30M in a series B investment round to support the clinical development of its lead product, STMC-103H. The series B funding involved participation from […]
The DuPont Human Microbiome Venture today announced a research partnership with The Procter & Gamble Company (P&G), focusing on the discovery and development of innovative next generation probiotics (NGPs) for human health. Over the past […]
BiomX Inc. (NYSE American: PHGE), a clinical stage company developing natural and engineered phage therapies that target specific pathogenic bacteria, today announced that it has entered into a collaboration with Boehringer Ingelheim to utilize the […]
Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres”), a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease, today […]
Micronoma, an early cancer-detection biotech that seeks to develop and commercialize a minimally invasive, microbiome-based method, announced today that it has closed a $3 million seed financing round led by microbiome-focused investor, SymBiosis, LLC. The […]